Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ADAPTela trial: what clinicians have said so far
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
- NCT07242352 ↗
- Recruiting
- Women's Cancer Study Group GmbH
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ADAPTela yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ADAPTela so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Dynamic Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- Early Breast Cancer (ADAPTela)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Cancer; HR+/HER2- Breast Cancer
- Interventions
- Elacestrant; Standard-of-care endocrine treatment
- Arms
- Elacestrant upfront (ELA) · Experimental
- Standard-of-care endocrine treatment (SoC-ET) · Active comparator
- Enrollment
- 1,520 (estimated)
- Primary outcomes
- 5-year invasive disease-free survival (iDFS)
- Sponsor
- Women's Cancer Study Group GmbH with Berlin-Chemie Menarini
- Start
- Apr 29, 2026
- Primary completion
- Sep 30, 2033 (estimated)
- Results posted
- No
- Registry record
- NCT07242352 · updated Aug 7, 2026